Oncology · Tyrosine Kinase InhibitorRegulatory Approvalcommercialmid-term

Alembic submits ANDA for Bosutinib Monohydrate

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/18/2026, 12:30:47 PM

Assessment confidence: 80% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

Alembic's submission of an ANDA for Bosutinib Monohydrate signifies a potential increase in competition within the oncology market. This could impact pricing strategies and market share for existing Bosutinib products, necessitating a strategic response from incumbent companies. Regulatory context from FDA (FDA TA — ANDA220639) supports the near-term read. Assessment grounded in 27 ranked evidence items (21 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Alembic's entry on market dynamics and pricing strategies for existing Bosutinib products. The strongest clinical anchor is A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies (ClinicalTrials.gov), entity match (cancer). In Oncology · Tyrosine Kinase Inhibitor, 8 regulatory and 5 competitive items passed relevance filtering for Alembic Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer (Humanexa Signals) — entity match (cancer). Secondary pressure from FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer. This submission indicates Alembic's intent to enter the market for Bosutinib, potentially increasing competition in the oncology space.

Regulatory Outlook

Regulatory risk is concentrated around FDA TA — ANDA220639 (FDA). Entity match (alembic pharmaceuticals); Regulatory pathway relevance (nda). The ANDA submission indicates a regulatory pathway that could lead to increased availability of Bosutinib, impacting compliance and approval timelines for existing products.

Key Risks

Elevated medium regulatory exposure for Alembic Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The entry of Alembic into the Bosutinib market could lead to price competition, affecting revenue and market positioning for existing products. Companies will need to reassess their pricing strategies to maintain market share.
The primary objective of the study for Cohort 1 and Cohort 2 is to assess the anticancer activity of emavusertib in combination with zanubrutinib in participants with CLL.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in adjuvant treatment for early-stage ER-positive breast cancer, a significant advancement in over 20 years.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in early-stage ER-positive breast cancer, impacting existing therapies.
Oncology · Immune-Mobilizing T-cell Receptors · Regulatory Approval · The approval of tebentafusp positions it as a key player in the uveal melanoma market, potentially impacting competitors developing similar therapies.

What Would Change This Assessment

This becomes more urgent if Monitor the review status and timeline for approval of ANDA209543.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA TA — ANDA220639
FDAhigh relevance
Entity match (alembic pharmaceuticals); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — ANDA220499
FDAhigh relevance
Entity match (alembic pharmaceuticals); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — BOSUTINIB MONOHYDRATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TRETINOIN (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — ANDA219413
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — VYEPTI (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HALOPERIDOL (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
ClinicalTrials.govhigh relevance
Entity match (cancer)
FDA document
View source
The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer
ClinicalTrials.govhigh relevance
Entity match (cancer)
FDA document
View source
ASk Questions in GYnecologic Oncology (ASQ-GYO)
ClinicalTrials.govhigh relevance
Entity match (oncology)
FDA document
View source
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ClinicalTrials.govhigh relevance
Entity match (cancer)
FDA document
View source
Evaluation of Interactions and Group Processes in Multidisciplinary Tumor Boards in Gynecologic Oncology
ClinicalTrials.govhigh relevance
Entity match (oncology)
FDA document
View source
Assessment of the Efficacy of Highly Standardized Ginger and Perilla Nutraceutical (Dispepril®) in Improving Gastric and Intestinal Symptoms in Patients With Functional Dyspepsia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Contribution of Immersive Virtual Reality to Standardized Rehabilitation Program for Upper Limb Chronic Pain: A Single-Case Experimental Design Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Entity match (cancer)
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Entity match (cancer)
[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Tebentafusp establishes first-line treatment for HLA-A*02:01-positive uveal melanoma
Humanexa Signalshigh relevance
Entity match (oncology)
FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer
Humanexa Signalshigh relevance
Entity match (cancer)

Type 2 diabetes remission in gynaecologic oncology patients completing an acute preoperative weight loss protocol: a case series.
PubMedhigh relevance
Entity match (oncology)
FDA document
View source
Discovery of azaindole/indole-fused pyrimidine tetracyclic scaffolds as novel potent CDK7 inhibitors.
PubMedhigh relevance
Entity match (cancer)
FDA document
View source
Targeting the BMX in cancer: molecular mechanisms and emerging therapeutic strategies.
PubMedhigh relevance
Entity match (cancer)
FDA document
View source
Self-perceived learning outcomes of academic detailing discussing rational therapy with proton pump inhibitors among general practitioners in Norway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of caffeine gum on same-day and subsequent neuromuscular performance under a standardized resistance-priming condition in male basketball players.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Mechanisms of traditional Chinese medicine in enhancing the efficacy and reducing the toxicity of immune checkpoint inhibitors via regulation of the tumor microenvironment and gut microbiota.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Systematic identification of bacterial neuraminidase inhibitors from Psoralea corylifolia using ultrafiltration-UPLC-Q-Orbitrap-MS and molecular dynamics.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Alembic Pharmaceuticals
Cancer
Oncology

Commercial impact

medium

The entry of Alembic into the Bosutinib market could lead to price competition, affecting revenue and market positioning for existing products. Companies will need to reassess their pricing strategies to maintain market share.

Regulatory impact

medium

The ANDA submission indicates a regulatory pathway that could lead to increased availability of Bosutinib, impacting compliance and approval timelines for existing products.

What to watch

Monitor the review status and timeline for approval of ANDA209543.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.